Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | FPR1 | P21462 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.34 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19367721 | 0.77 | CYP2C9 (0.55) | CYP2C9CYP2C19 | |
| SCHEMBL5378514 | 0.71 | RAB9A (0.40) | HSP90AA1HSP90AB1NOS1RAB9ACYP2C9 | |
| SCHEMBL28044678 | 0.69 | KEAP1 (0.52) | MAPTPTGES2 | |
| SCHEMBL23320080 | 0.68 | RAB9A (0.48) | HSP90AA1HSP90AB1NOS1RAB9AMAPK1 | |
| SCHEMBL20033972 | 0.66 | HSP90AA1 (0.51) | HSP90AA1HSP90AB1NOS1RAB9A | |
| SCHEMBL31011102 | 0.65 | ALDH1A1 (0.50) | SLC22A12CYP2C9CYP2C19 | |
| SCHEMBL5369097 | 0.65 | TSHR (0.42) | HSP90AA1HSP90AB1NOS1RAB9AMAPK1 | |
| SCHEMBL23719141 | 0.64 | TSHR (0.53) | RAB9A | |
| SCHEMBL27535438 | 0.63 | HSP90AA1 (0.46) | HSP90AA1HSP90AB1NOS1RAB9A | |
| SCHEMBL23320044 | 0.63 | RAB9A (0.46) | HSP90AA1HSP90AB1RAB9ACYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170267668-A1 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD. (GB) | 2017-09-21 | — | — | US | disclosed |
| US-20170267668-A1 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD. (GB) | 2017-09-21 | — | — | US | disclosed |
| WO-2016026772-A1 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD (GB) | 2016-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267668-A1 | PHARMACEUTICAL COMPOUND | TDO2, IDO1, IDO2 | SLC22A12 1875/4885HSP90AA1 4820/4885HSP90AB1 4703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.